Urovant Sciences (Nasdaq: UROV) today reported financial results
for the three months ended June 30, 2020.
The first quarter of fiscal 2020 saw the Company achieve a
number of significant operational milestones as it embarked on the
build out of both its commercial and market access teams and
completed enrollment in the Phase 2a study of vibegron for
irritable bowel syndrome (IBS) pain.
“We continued to make important progress in the first fiscal
quarter of 2020. We significantly enhanced the commercial and
market access capabilities we need to successfully launch
vibegron,” said James Robinson, president and chief executive
officer of Urovant Sciences. “In addition, we continue to maximize
the value of vibegron and have completed enrollment in our Phase 2a
study of vibegron for IBS pain, an indication for which there are
no currently marketed drugs.”
Urovant Recent Business Highlights
- Completed enrollment in the Phase 2a study of vibegron for IBS
pain.
- Made significant progress in the hiring of customer-facing
personnel and are nearing completion of our sales leadership,
market access, and medical science liaison teams.
- Initiated an unbranded campaign to help inform and support
patients with overactive bladder (OAB), which included the launch
of an OAB-focused community website called bladderchatter.com.
Expected Upcoming Events
- Topline results from vibegron trial in IBS-associated pain
expected in Q4 2020.
- URO-902 Data and Safety Monitoring Board data review and
decision to move from cohort 1 to cohort 2 in Phase 2a trial
expected by early 2021.
- The U.S. Food and Drug Administration (FDA) Prescription Drug
User Fee Act (PDUFA) date for vibegron in OAB is December 26,
2020.
First Fiscal Quarter 2020 Financial Summary
For the quarter ended June 30, 2020, total operating expenses
were $28.8 million, comprised of research and development expenses
of $16.3 million and general and administrative expenses of $12.5
million. Net loss for the quarter ended June 30, 2020 was $30.5
million, or $0.99 per share. Cash used in operations was $30.8
million. As of June 30, 2020, total cash was $63.0 million.
Note to Investors
As previously announced, Urovant will hold a conference call
today, August 13, 2020, to discuss financial results from the first
fiscal quarter ended June 30, 2020. The call will begin at 1:30
p.m. Pacific, 4:30 p.m. Eastern, and you may listen to this call by
dialing (866) 470-1049 for domestic callers or (409) 217-8245 for
international callers and entering conference ID 7356668. A replay
of the call will be available approximately four hours after the
call and accessible for 7 days at (855) 859-2056, conference ID
7356668. A webcast will be archived on the Investor Relations page
of the Urovant Sciences website immediately after the call and
available for at least 30 days.
About Urovant Sciences
Urovant Sciences is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for urologic conditions. The
Company’s lead product candidate, vibegron, is an oral, once-daily
small molecule beta-3 agonist that is being evaluated for
overactive bladder (OAB). Urovant Sciences reported positive data
from the vibegron 12-week, Phase 3 pivotal EMPOWUR study and
demonstrated favorable longer-term efficacy, safety, and
tolerability in a 40-week extension study. The Company submitted a
New Drug Application to the U.S. Food and Drug Administration
seeking approval of vibegron for the treatment of patients with OAB
in December 2019. Vibegron is also being evaluated for treatment of
OAB in men with benign prostatic hyperplasia (OAB+BPH) and for
abdominal pain associated with irritable bowel syndrome (IBS).
Urovant’s second product candidate, URO-902, is a novel gene
therapy being developed for patients with OAB who have failed oral
pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitovant
Biopharma Ltd., which is a wholly owned subsidiary of Sumitomo
Dainippon Pharma Co., Ltd., intends to develop novel treatments for
additional urologic diseases. Learn more about us at
www.urovant.com.
About Sumitovant Biopharma Ltd.
Sumitovant is a global
biopharmaceutical company with offices in New York City and London.
Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon
Pharma. Sumitovant is the majority shareholder of Myovant and
Urovant, and wholly owns Enzyvant, Spirovant, and Altavant.
Sumitovant's promising pipeline is comprised of early through
late-stage investigational medicines across a range of disease
areas targeting high unmet need. For further information about
Sumitovant, please visit
https://www.sumitovant.com.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma is
among the top-ten listed pharmaceutical companies in Japan,
operating globally in major pharmaceutical markets, including
Japan, the U.S., China, and the European Union. Sumitomo Dainippon
Pharma is based on the merger in 2005 between Dainippon
Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd.
Today, Sumitomo Dainippon Pharma has more than 6,000 employees
worldwide. Additional information about Sumitomo Dainippon Pharma
is available through its corporate website at
https://www.ds-pharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include all statements that are
not historical statements of fact and statements regarding the
Company’s intent, belief, or expectations, and can be identified by
words such as “anticipate,” “believe,” “can,” “continue,” “could,”
“estimate,” “expect,” “intend,” “likely,” “may,” “might,”
“objective,” “ongoing,” “plan,” “potential,” “predict,” “project,”
“should,” “strive,” “to be,” “will,” “would,” or the negative or
plural of these words or other similar expressions or variations,
although not all forward-looking statements contain these
identifying words. In this press release, forward-looking
statements include, but are not limited to, statements regarding
the Company’s plans and strategies for the development and
commercialization of innovative therapies for the treatment of
urological conditions; including expectations regarding the
clinical development of vibegron in patients with overactive
bladder (OAB), the clinical development of URO-902 in patients with
OAB, the clinical development of vibegron in patients with OAB+BPH
and IBS-pain, and the related status of FDA approval. The Company’s
forward-looking statements are based on management’s current
expectations and beliefs and are subject to a number of risks and
uncertainties that could lead to actual results differing
materially from those projected, forecasted, or expected. Although
the Company believes that the assumptions underlying these
forward-looking statements are reasonable, they are not guarantees
and the Company can give no assurance that its expectations will be
attained. Factors that could materially affect the Company’s
operations and future prospects or which could cause actual results
to differ materially from expectations include, but are not limited
to: the Company’s limited operating history and the fact that it
has never generated any product revenue; the Company’s ability to
achieve or maintain profitability in the future; the Company’s
dependence on the success of its lead product candidate, vibegron;
the impact on the Company’s business, financial results, results of
operations and ongoing clinical trials from the effects of the
COVID-19 pandemic; the Company’s ability to satisfy future funding
needs on commercially reasonable terms and conditions if at all;
the Company’s dependence on Sumitomo Dainippon Pharma and its
affiliates to provide loan funding under the Company’s loan
agreement and commercial and operational support for the Company’s
product candidates and the significant control Sumitomo Dainippon
Pharma Co., Ltd., through its wholly owned subsidiary, Sumitovant
Biopharma Ltd., can assert over the Company through its ownership
of the Company’s common shares and control of the Company’s board
of directors; the Company’s reliance on its key scientific, medical
or management personnel, and on certain affiliates to provide
certain services to the Company; risks related to clinical trials,
including uncertainties relating to the success of the Company’s
clinical trials for vibegron and URO-902 and any future therapy or
product candidates; uncertainties surrounding the regulatory
landscape that governs gene therapy products; the Company’s
dependence on Merck Sharp & Dohme Corp. and Ion Channel
Innovations, LLC to have accurately reported results and collected
and interpreted data related to vibegron and URO-902 prior to the
Company’s acquisition of the rights related to these product
candidates; reliance on third parties to conduct, supervise, and
monitor the Company’s clinical trials; reliance on a single
supplier for the enzyme used to manufacture vibegron; the ability
to obtain, maintain, and enforce intellectual property protection
for the Company’s technology and products; risks related to
significant competition from other biotechnology and pharmaceutical
companies; the failure to achieve the market acceptance necessary
for commercial success for a product candidate; and other risks and
uncertainties listed in the Company’s filings with the United
States Securities and Exchange Commission (SEC), including under
the heading “Risk Factors” in the Company’s most recently filed
Annual Report on Form 10-K and any subsequent Quarterly Reports on
Form 10-Q filed with the SEC, as such risk factors may be amended,
supplemented, or superseded from time to time by other filings with
the SEC. You should not place undue reliance on the forward-looking
statements in this press release, which speak only as of the date
hereof, and, except as required by law, the Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances after the date of such statements.
UROVANT SCIENCES LTD.
Condensed Consolidated
Statements of Operations
(unaudited; in thousands, except
share and per share data)
Unless otherwise noted, the three months
comparisons are to the prior fiscal year comparable period ended
June 30, 2019.
Three Months Ended June
30,
2020
2019
Operating expenses:
Research and development(1)
$
16,354
$
22,014
General and administrative(2)
12,489
5,465
Total operating expenses
28,843
27,479
Other expense:
Interest expense, net
(1,443
)
(513
)
Loss on disposal of property and
equipment
—
(236
)
Other expense, net
(118
)
(190
)
Loss before provision for income taxes
(30,404
)
(28,418
)
Provision for income taxes
90
67
Net loss
$
(30,494
)
$
(28,485
)
Net loss per common share—basic and
diluted
$
(0.99
)
$
(0.94
)
Weighted average common shares
outstanding—basic and diluted
30,705,334
30,325,169
(1)
Includes $369 and $265 of share-based
compensation during the three months ended June 30, 2020 and 2019,
respectively
(2)
Includes $1,669 and $782 of share-based
compensation during the three months ended June 30, 2020 and 2019,
respectively.
Condensed Consolidated Balance
Sheets
(unaudited; in thousands)
Unless otherwise noted, the three months
comparisons are to the prior fiscal year comparable period ended
March 31, 2020.
June 30,
2020
March 31,
2020
Assets
Current assets:
Cash
$
63,039
$
51,414
Restricted cash
250
243
Due from Sumitovant Biopharma Ltd.
—
172
Prepaid expenses and other current
assets
8,980
6,489
Total current assets
72,269
58,318
Property and equipment, net
1,237
1,210
Operating lease right-of-use assets
3,939
3,135
Restricted cash, net of current
portion
623
623
Other assets
69
9
Total assets
$
78,137
$
63,295
Liabilities and Shareholders'
Deficit
Current liabilities:
Accounts payable
$
130
$
1,589
Accrued expenses
23,098
21,756
Due to Roivant Sciences Ltd.
2
31
Current portion of share-based
compensation liabilities
6,919
7,204
Current portion of operating lease
liabilities.
422
351
Total current liabilities
30,571
30,931
Share-based compensation liabilities, net
of current portion
370
32
Related-party long-term debt
128,270
87,252
Operating lease liabilities, net of
current portion
3,862
3,086
Total liabilities
163,073
121,301
Total shareholders' deficit
(84,936
)
(58,006
)
Total liabilities and shareholders'
deficit
$
78,137
$
63,295
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200813005140/en/
Investor and Media inquiries: Ryan Kubota 949.769.2706
ryan.kubota@urovant.com
Urovant Sciences (NASDAQ:UROV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Urovant Sciences (NASDAQ:UROV)
Historical Stock Chart
From Apr 2023 to Apr 2024